hashimoto disease and semaglutide Hashimoto's Tirzepatide: Safety and Monitoring Guide Hashimoto's and GLP-1: what thyroid

These findings highlight the chronic nature of obesity and suggest that ongoing treatment is necessary to maintain improvements in weight and overall health for patients, similar to the management of other chronic conditions such as diabetes or hypertension." An Eli Lilly and Company spokesperson told Newsweek : "Obesity is a chronic progressive disease, and people living with obesity deserve care that reflects that reality

Why It Matters The findings come as usage of weight-loss jabs surges in the United States a Rand Corporation survey from last August found that nearly 12 percent of Americans had used glucagon-like peptide (GLP-1) drugs, including Wegovy and Mounjaro, for weight loss

Concomitant diseases included heart failure (23%), hypertension (91%), previous ischemic stroke (12%), previous MI (40%), and peripheral artery disease (16%)

The FDA ended the shortage February 21, 2025, and clarified on April 1, 2026 that B12 add-ons alone do not automatically qualify a script

This product has not been evaluated by the FDA or any regulatory authority for medical use